Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 89-91 , January 2009

Positive surgical margins: The argument for androgen deprivation and chemotherapy

  • Celestia S. Higano, M.D.

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-206-288-1152; fax: +1-206-288-1196

References 

  1. Vis AN, Schroder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol. 2006;50(2):258–265
  2. Tsai HK, Chen MH, McLeod DG, et al. Cancer specific mortality after radiation with short-course hormonal therapy or radical prostatectomy in with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006;107:2563–2597
  3. Yossepowitch O, Eggner SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2007;Oct 12;[Epub ahead of print]
  4. D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002;20:4567–4573
  5. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet. 1998;351:1451–1467
  6. Messing EM, Manola J, Yao J, et al. Immediate vs. deferred androgen deprivation treatment in patients with node-positive cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–479
  7. Tannock I, de Wit R, Berry WR, et al. TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512
  8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520
  9. Wang J, Halford S, Rigg A, et al. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int. 2000;86(6):675–680

PII: S1078-1439(08)00077-X

doi: 10.1016/j.urolonc.2008.04.003

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 89-91 , January 2009

Article Tools